78 results about "Liver Cirrhoses" patented technology

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of drugs for resisting liver cirrhosis and inhibiting liver inflammations, the drugs comprise lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the drugs are ground and then mixed with food to prepare a drug mixture, and the drug mixture is prepared into the drug for resisting liver cirrhosis and inhibiting liver inflammations. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%, and the mechanism of the lanthanum carbonate for treating the liver cirrhosis is as follows: interference or blocking of activation and proliferation of hepatic stellate cells, inhibition of extracellular matrix generation and promotion of extracellular matrix degradation. According to the invention, a rat liver cirrhosis model is constructed through chemical induction, and the effects of reversing liver cirrhosis and inhibiting liver inflammation are found when a rat is treated by taking lanthanum carbonate orally, so that a new candidate drug is provided for clinical treatment of liver cirrhosis.

The invention discloses a liver cirrhosis microbial marker as well as a screening method and application thereof, and solves the technical problems of few markers, small clinical queue scale and unknown effectiveness in predicting the future liver cirrhosis risk in the existing intestinal flora biomarker research. The method comprises the following steps: by integrating whole genome association research data (GWAS) and 16S rRNA gene sequencing data, screening out candidate microbial differential bacteria related to liver cirrhosis by adopting difference analysis; in combination with LDSC analysis and a double-sample Mendel randomization method, MR related bacteria and LDSC genetic related bacteria are screened from the aspects of causal correlation and genetic correlation; taking an intersection of the differential bacteria, the MR related bacteria and the LDSC genetic related bacteria as a marker; finally, model training is conducted through a machine learning algorithm by means of a data set with sample labels, individual liver cirrhosis risk prediction labels are output, early screening of liver cirrhosis is achieved, and the method can be widely applied to the technical field of intestinal microorganism and data mining.

The invention discloses an application of a biomarker in evaluating the risk of progressing from autoimmune hepatitis to cirrhosis. The biomarker comprises immune globulin G, and / or an antinuclear antibody, and / or aspartate aminotransferase and alanine aminotransferase. Independent predictive factor indexes of the liver cirrhosis risk of an autoimmune hepatitis patient in the biomarker are as follows: an antinuclear antibody ANA index: log2ANA is greater than or equal to 1.62; the AAR index of the ratio of aspartate aminotransferase to alanine aminotransferase is as follows: AAR is greater than or equal to 1.62; the immune globulin G, namely the IgG index, is greater than or equal to 30.3 g / L. The problems that in the prior art, an AIH risk model does not take cirrhosis as the outcome, visual presentation is lacked, prediction efficiency is insufficient, and clinical early-stage accurate risk layering and diagnosis and treatment decision requirements are difficult to meet are solved.

The present application relates to the technical field of medical information processing, in particular to a liver cirrhosis prognosis risk detection system. After each detection of the patient's liver by the system, the image data can quantify the image liver cirrhosis risk from the morphological changes in the liver region. According to the difference between the actual detection data and the prediction data, and the prognosis response non-normality, the disease progression index is determined. The drug adjustment data is used to determine the drug adjustment degree, and then the liver cirrhosis progression index is obtained. The data lag and the liver cirrhosis progression index are quantified to adjust the detection frequency of the system. The present application enables the system to effectively respond to the patient's condition and generate an effective early warning signal to remind medical staff to perform liver detection when necessary.

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

The invention belongs to the technical field of biotechnology, and particularly relates to application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit and a detection method. The invention provides an application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit for liver cirrhosis diagnosis / treatment and a detection method of a serum exosome MZF1 protein. The exosome MZF1 protein is used as a marker, a valuable reagent or drug application prospect is provided for early diagnosis and treatment of liver cirrhosis, and help is provided for analysis of more serum exosome proteins applied to liver cirrhosis markers.

The present invention relates to the field of liver disease, and more particularly to a method for determining the presence of chronic plus acute liver failure or for determining the risk of developing ACLF in a patient suffering from cirrhosis or a delayed early stage of ACLF. The invention also relates to a method for distinguishing patients suffering from decompensated liver cirrhosis, acute decompensated liver cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, a method for determining the degree of systemic inflammation and a method for determining the presence of a bacterial infection with sepsis.

The invention relates to a patient decision support system and operating method based on self-care algorithms that evaluate patient activity for patients diagnosed with liver cirrhosis, which is intended to monitor and manage patients' health conditions, provides regular data tracking and personalised recommendations, tracks patients' daily and weekly activities, medication use, diet, and exercise routines, collects and evaluates the data, and presents user-specific recommendations, and which uses artificial intelligence and care algorithms to determine, on the basis of the patient's health data, which treatment and care pathways are the most appropriate.

The invention specifically discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. Experimental results show that the compound shows remarkable anti-inflammatory activity in a lipopolysaccharide stimulated RAW 264.7 cell model, and the anti-inflammatory activity is obviously superior to that of a positive drug dexamethasone; the compound shows a remarkable lipid accumulation inhibition effect in a HepG2 cell model treated by free fatty acid, is obviously superior to a positive drug obeticholic acid, and can be used for developing drugs for treating the non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis and related liver cirrhosis.

The invention relates to a model for predicting the death risk of patients suffering from liver cirrhosis critically ill diseases, and belongs to the technical field of medical examination and severe medicine. Aiming at the problems of complexity and time consumption of existing prognostic scoring of cirrhosis, the invention provides an anion gap AG calculated by using Na < + >, K < + >, Cl <-> and HCO3 <-> of intraday venous blood in an ICU (Intensive Care Unit) as a biomarker, and a high-risk threshold value that AG is greater than 16mmol / L is set. Researches show that the death risks of high-AG patients in 30 days, 60 days and hospitalization are obviously increased, the HR after correction is respectively 1.920, 1.793 and 1.764, and the predicted efficiency AUC is approximately equal to 0.71 and is equivalent to MELD, SOFA, GCS and OASIS. The system comprises an electrolyte detection module, an AG calculation module, a risk grading module and a display module, and can be embedded into an existing ICU information platform to realize rapid, simple, convenient and accurate early death risk early warning.

The application belongs to the field of biological medicine, and particularly relates to a compound for treating liver cirrhosis portal hypertension and application thereof. The compound can be used for preparing a medicine for treating liver cirrhosis portal hypertension. The medicine can achieve the treatment purpose of improving LSEC dysfunction and reducing liver cirrhosis portal pressure without affecting the circulating pressure.

The invention relates to the technical field of medicine, and particularly discloses a liver cirrhosis specific intestinal flora marker composition and application of the liver cirrhosis specific intestinal flora marker composition in noninvasive diagnosis. The intestinal microbial flora is selected from the group consisting of clostridium, Bacteroides, Thalictrum, Wehonor genus, Streptococcus genus, Klebsiella genus, and Prevotella genus; according to the method, a non-invasive solution is provided for screening and diagnosis of liver cirrhosis by detecting a synergistic change mode of specific florae such as clostridium, bacteroides, thickenella, prevotella, Wehonor, streptococcus and klebsiella in an excrement sample; the limitation that traditional liver needle biopsy is invasive and imaging examination is insensitive to early-stage lesions is avoided.

The invention relates to the technical field of medicines, in particular to application of allogenic liver precursor cells in preparation of a medicine for treating liver cirrhosis, and the liver cirrhosis is decompensated liver cirrhosis. The allogenic liver precursor cells degrade extracellular matrix, fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) through paracrine MMPs to promote hepatocyte regeneration and repair and the like, so that the liver cirrhosis is relieved and improved.

The application discloses an intestinal microbial marker combination for cirrhosis diagnosis and application thereof, which is composed of 8 specific intestinal bacterial species. The application accurately identifies the core combination from 181 differential characteristics by performing metagenomic sequencing on fecal samples of cirrhosis patients and healthy controls, and combining random forest, LASSO regression and recursive feature elimination algorithms. The random forest diagnosis model based on the 8 markers realizes an excellent performance of area under curve (AUC) 0.841, sensitivity 84.3% and specificity 83.7% on a completely independent test set, and the performance does not decrease compared with the full feature model in the case of reducing the number of characteristics by 86.9%. The marker combination provided by the application is highly simplified and has strong discrimination, and provides a clear and efficient microbiological basis and technical scheme for developing a cirrhosis non-invasive diagnosis kit, a gene chip and other products based on intestinal flora.

The invention discloses a non-invasive portal vein hemodynamic parameter measuring method and device and a medium, and relates to the technical field of medical detection equipment and biomedical signal processing.The method comprises the steps that abdominal epidermal potential distribution data is collected, a conductivity change area is recognized, and a portal vein trunk three-dimensional thermodynamic diagram is generated; peak coordinates of the portal vein trunk three-dimensional thermodynamic diagram are extracted, a portal vein trunk space positioning coordinate set is obtained, a graphene quantum tunneling sensor is driven to be attached to the abdominal skin surface of the patient based on the portal vein trunk space positioning coordinate set, and an attachment ready signal is output; based on the attachment ready signal, an original current data flow is collected, temperature drift correction is performed on the original current data flow, the original current data flow is converted into an instantaneous flow velocity, and a time-flow velocity sequence is generated. The microcosmic dynamic of early portal extravasated blood is captured, the pathological low-speed event which cannot be detected by the traditional technology is identified, and a non-invasive early warning index is provided for the liver cirrhosis progress risk.

The present application relates to the technical field of medical equipment, and particularly relates to a device for liver cirrhosis intractable ascites. The present application provides a device for liver cirrhosis intractable ascites, which is convenient to carry and low in use cost. The device for liver cirrhosis intractable ascites comprises a supporting cylinder, a transparent shell, a scale plate, a threaded sleeve, a connecting pipe and a pumping rod, the supporting cylinder is fixed with the transparent shell, the transparent shell is fixedly connected with the scale plate, one side of the supporting cylinder is fixedly connected with the threaded sleeve, the threaded sleeve is threadedly provided with the connecting pipe, the supporting cylinder is slidably provided with the pumping rod capable of pumping liver ascites, and the pumping rod is slidably connected with the inside of the transparent shell. The device is small in overall space occupation, can be timely sent to the patient side to pump liver ascites in special situations, is more convenient to use, and is simple in design and low in cost.

The invention relates to the technical field of biological medicine, in particular to a non-medicinal part and extract of Mongolian medicine scabiosa and application of the non-medicinal part and extract in the aspect of liver fibrosis resistance. The scabiosa has the effects of clearing heat, improving eyesight, clearing heat and coordinating the day. The Tibetan medicine uses papaveris meconopsis as the dry inflorescence of meconopsis longleaf, meconopsis valvata and meconopsis wuveitana, and the effects of the two are considered to be similar. The invention aims to provide a technical scheme of the non-medicinal part and the extract of scabiosa scabiosa in anti-hepatic fibrosis and research and development of corresponding medicines, and application of the non-medicinal part or the extract of the non-medicinal part in preparation of medicines for treating and relieving liver injury, hepatic fibrosis, liver cirrhosis and the like. Pharmacological studies on inflorescence, stem leaves, meconopsis wuveolens chemical components and in-blood component networks of scabiosa coreana show that the scabiosa coreana and meconopsis wuveolens have similar effects, have obvious effects of relieving carbon tetrachloride acute liver injury, resisting hepatic fibrosis and reducing AST and ALT, and belong to low-toxicity drugs.

Adult form glycogen storage disease type III (GSD III) is an orphan neuromuscular disorder caused by a deficiency of glycogen debranching enzyme. Long-term complications include progressive liver fibrosis, hepatic failure, and end-stage liver cirrhosis, and progressive muscle myopathy. Presently, there are no clinically approved therapies or cures for GSD III. Disclosed herein are compositions for and methods of treating and / or preventing GSD III disease progression.

The invention discloses an enteral nutrition infusion regulation and control method and system for patients with cirrhosis ascites, and relates to the technical field of medicines.The enteral nutrition infusion regulation and control method comprises the following steps that basic illness state information, intestinal function information and laboratory nutrition indexes of the patients with cirrhosis ascites are collected; performing analysis to obtain grading characteristics of the basic illness state information, absorption capacity characteristics of the intestinal function information and supply and demand characteristics of the laboratory nutrition indexes, calculating individual enteral nutrition demand parameters of the patient based on the grading characteristics, the absorption capacity characteristics and the supply and demand characteristics, and generating an initial enteral nutrition infusion scheme. Based on comprehensive evaluation of basic illness conditions, intestinal functions and laboratory indexes, nutritional requirement parameters are calculated in combination with correction coefficients, and it is ensured that an initial scheme adapts to individual characteristics of patients. Through set dose trial verification and real-time monitoring, abnormal types such as intestinal tolerance, liquid electrolyte balance, nutritional state and special illness conditions can be identified in time.

The invention provides a liver cirrhosis complication early screening marker based on plasma proteomics. The liver cirrhosis complication early screening marker comprises the following five proteins: GDF15, NOTCH2, PROC, GGT1 and COL4A1. The early screening marker provided by the invention can provide ultra-early warning within 16 years before disease attack, is high in prediction accuracy, and is superior to the conventional model in short-term and long-term prediction aspects; meanwhile, a key proteome pathway is disclosed, and reference can be provided for clinical application and prevention strategies. The invention also provides application of the liver cirrhosis complication early screening marker and a corresponding early screening kit.

The application provides a liver fibrosis marker circRNA and application thereof, and belongs to the field of biological medicine.The circRNA is circSMAD2, and the nucleotide sequence is shown as SEQ ID NO.1.The application finds through experiments that circSMAD2 is significantly highly expressed in human liver cancer, liver cirrhosis serum and liver fibrosis mouse primary hepatic stellate cells, and therefore, circSMAD2 can be used as a basis for clinical diagnosis of liver fibrosis.The application further constructs an adeno-associated virus AAV knockdown vector by using circSMAD2, and finds through in-vivo verification that circSMAD2 can significantly improve mouse liver fibrosis.Therefore, circSMAD2 can be used as a novel target and potential drug for clinical treatment of liver fibrosis, and provides a new direction for research and development of a therapeutic drug for liver fibrosis.

The application provides an AI treatment decision system for liver cirrhosis acute variceal hemorrhage, relates to the technical field of treatment decision, extracts a transient characteristic indicator of blood flow pressure from a pressure fluctuation signal, predicts a transient pressure peak of the portal vein blood flow during acute variceal hemorrhage through the transient characteristic indicator and a blood flow dynamic model, predicts a quasi-steady pressure field of the portal vein blood flow during acute variceal hemorrhage according to the gradient distribution of the portal vein blood flow pressure and an initial treatment strategy of acute variceal hemorrhage, performs multi-scale coupling on the transient pressure peak and the quasi-steady pressure field to obtain a coupling characteristic of the portal vein blood flow, and then uses the coupling characteristic of the blood flow pressure to perform hierarchical coupling adjustment on the treatment strategy of liver cirrhosis acute variceal hemorrhage. Based on the above scheme, hierarchical coupling of the treatment strategy of liver cirrhosis acute variceal hemorrhage can be realized, so that the prediction accuracy of the portal vein blood flow pressure during acute variceal hemorrhage can be improved.

The present disclosure relates essentially to a supplement, the function of which is to enhance immunity, prevent various diseases and assist in therapeutic treatments of various diseases, said supplement includes: 100 mg of lipoic acid, 1 mg of astaxanthin, 10 mg of glutathione, 5 mg of resveratrol, 5 mg of lycopene, 50 mg of epigallocatechin, 300 mg of curcumin, 400 mg of quercetin, 10 mg of coenzyme Q1 and 100 mg of dry açaí extract; formulated with the intention of combining substances that serve functions of assisting in the treatment of various diseases, such as: lipoic acid, which helps in the prevention of liver damage from intoxication, and can be used as a coadjuvant for the treatment of liver cirrhosis due to alcoholism and a coadjuvant for the treatment of diabetes and cataracts.

The invention belongs to the technical field of cellular immunotherapy, and particularly relates to a targeted FAP chimeric antigen receptor macrophage as well as a preparation method and application thereof. According to the invention, FAP is taken as a target spot to design a CAR carrier of a specific targeted activated hepatic stellate cell, and a CAR-M cell for treating hepatic fibrosis is constructed. The macrophage expressing the chimeric antigen receptor has a remarkable killing effect on FAP positive cells, and a new thought is provided for clinical treatment of hepatic fibrosis, liver cirrhosis and liver cancer.

The disclosure provides methods to reverse or regress fibrosis and / or liver cirrhosis in a subject in need thereof, using high-dose (pharmacologic) niacin, or a niacin analog thereof.

The present invention relates to novel spirohydantoin derivatives having metalloprotease ADAMTS-4 inhibitory activity and uses thereof. The spirohydantoin derivatives described in the present invention are useful for the prevention or treatment of diseases caused by liver damage, such as fatty liver, liver cirrhosis, and the like.

The invention discloses an application of DNase-1 in preparing a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction and related hepatic fibrosis and cirrhosis, and provides an application of DNase-1 in preventing and / or treating fatty liver diseases related to metabolic dysfunction and related hepatic fibrosis and cirrhosis for the first time. Through targeted degradation of NETs pathologically formed in the liver, the vicious circle of inflammation-injury-fibrosis is broken from the source, and a brand new treatment strategy with a clear mechanism is provided for the serious disease lacking an effective therapy.

The invention discloses an application of fenerenone in preparation of a medicine for treating liver fibrosis or liver cirrhosis related to a metabolism-related fatty liver disease (MAFLD). Experimental results show that the fenerenone can obviously improve the MAFLD-related hepatic fibrosis, and a new drug treatment choice is provided for the MAFLD-related hepatic fibrosis. Therefore, a novel therapeutic drug based on the fenerenone is developed and has important clinical significance and market value.

The present invention relates to a metal-organic framework for inhibiting the activity of M2 macrophages, and a pharmaceutical composition comprising same, wherein the metal-organic framework of the present invention is non-toxic to cells and can exhibit an effect of inhibiting the activity of M2 macrophages. More specifically, the metal-organic framework of the present invention can be provided as an anticancer composition for tumor-related macrophage-mediated diseases, particularly solid cancer, through the inhibition of M2 macrophages capable of increasing the expression of genes associated with parasite invasion, tissue remodeling, and tumor proliferation (immunomodulatory function), and can also be provided as a pharmaceutical composition for treating chronic infectious diseases, liver cirrhosis, obesity-related metabolic diseases, scar formation and idiopathic lung diseases.

The invention discloses a stem cell preparation for improving liver cirrhosis and a preparation method and application thereof, and relates to the technical field of stem cells. The stem cell preparation is prepared by mixing the following raw materials in percentage by weight with a sterile PBS (Phosphate Buffer Solution) to a constant volume: 0.2%-0.8% of mesenchymal stem cells, 0.5%-2% of soluble sodium hyaluronate, 0.5%-1.5% of vitamin A, 0.5%-1.5% of cortex dictamni lactone and 1.2%-1.8% of a common goldenrop soup extract. The stem cell preparation effectively inhibits activation of hepatic stellate cells and synchronously improves the liver function and oxidative stress level through multi-component synergy. According to the stem cell preparation, mesenchymal stem cells are taken as a core and are combined with a common goldenrop decoction extract and cortex dictamni lactone to synergistically play key roles in resisting inflammation and inhibiting activation of hepatic stellate cells; the vitamin A is used as an auxiliary component, so that the anti-oxidation and anti-proliferation effects are further enhanced. Under the support of a soluble sodium hyaluronate carrier, all the components construct a functional complementary synergistic treatment network, and the comprehensiveness and stability of the curative effect are remarkably improved.